Lazcluze (Lazertinib Mesilate Monohydrate)

Lazcluze (lazertinib mesilate monohydrate) is employed to treat cancers driven by EGFR mutations, primarily within the non‑small cell lung cancer (NSCLC) spectrum.

• EGFR mutation‑positive NSCLC: provides tumor growth inhibition and prolongs progression‑free survival in patients whose tumors harbor activating EGFR alterations.
• NSCLC with EGFR T790M resistance mutation: overcomes acquired resistance to first‑generation EGFR inhibitors, restoring clinical response.
• Advanced/metastatic EGFR‑mutated NSCLC: used as first‑line therapy to delay disease progression and improve overall outcomes.

• Lazertinib mesilate monohydrate binds selectively to the ATP‑binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. By inhibiting both wild‑type EGFR and mutant forms such as L858R, exon 19 deletions and the resistance‑associated T790M substitution, it blocks downstream signaling through the MAPK and PI3K‑AKT pathways, thereby suppressing tumor cell proliferation, inducing apoptosis in malignant cells.

Lazcluze may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: frequent watery stools that may lead to dehydration.
• Rash: acne‑like skin eruptions, often on the face or trunk.
• Nausea: mild to moderate feeling of sickness.
• Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects

• Interstitial lung disease: inflammation of lung tissue that can be life‑threatening.
• Hepatic enzyme elevation: significant increase in ALT/AST indicating liver injury.
• QT interval prolongation: cardiac electrical disturbance that may cause arrhythmia.

When prescribing Lazcluze, clinicians should observe several safety measures to minimize risk.

• Monitor liver function: obtain baseline and periodic ALT/AST tests.
• Assess cardiac status: perform ECG to detect QT prolongation before and during therapy.
• Evaluate for pulmonary symptoms: watch for cough or dyspnea indicating interstitial lung disease.
• Avoid use in patients with known hypersensitivity to lazertinib or excipients.
• Review concomitant medications: adjust doses of drugs that affect CYP3A4 metabolism.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lazcluze can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce plasma concentrations of lazertinib.
• Antacids containing aluminum or magnesium: may decrease oral absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may increase lazertinib exposure, requiring dose consideration.
• QT‑prolonging agents (e.g., sotalol, quinidine): additive risk of cardiac arrhythmias.
• Warfarin: potential alteration of anticoagulant effect, monitor INR.